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Introduction. The study aimed to evaluate the performance of multiparametric magnetic resonance imaging (mpMRI) 
and the Martini model to predict extraprostatic extension (EPE) and biochemical recurrence (BCR) of prostate cancer (PCa).
Materials and methods. 61 patients underwent a radical laparoscopic prostatectomy. The preoperative risk of EPE was 
determined using mpMRI and the Martini model.
Results. MpMRI predicts the presence of EPE of PCa with a sensitivity and specificity of 47.4% and 85.7%, respectively 
(AUC 0.66, 95% CI: 0.51–0.82, p = 0.046). The Martini model’s sensitivity was higher, but the specificity was lower than that 
of mpMRI and was 84.2% and 66.7%, respectively (AUC 0.78, 95% CI: 0.66–0.89, p < 0.001). Univariate and multivariate Cox 
analysis indicated that EPE in mpMRI (HR 6.6, 95% CI: 1.8–24.1), and the presence of positive surgical margins (PSM) (HR 
7.1, 95% CI: 1.9–26.7) are independent factors increasing the probability of BCR.
Conclusions. MpMRI and Martini model are valuable tools in local staging of PCa, managing and predicting the oncolo-
gical treatment outcomes of patients with PCa.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed mali-
gnant neoplasm in men in the world [1]. A radical prostatectomy 
(RP), next to radiotherapy (RT), is the treatment of choice in 
patients with non-metastatic PCa [2]. Biochemical recurrence 
(BCR) after RP affects 30% of patients and is one of the risk 
factors for disease progression and death [3, 4]. The confirmed 
risk factors for the occurrence of BCR in the postoperative report 
are: positive surgical margins (PSM) and extraprostatic extension 
(EPE)/locally advanced disease (stage T3–T4) [5]. The presence of 
the above parameters determines adjuvant treatment, i.e. local 
RT, aimed at reducing the risk of disease recurrence. 
Precise local staging is an essential clinical issue due to 
its significance in treating patients with non-metastatic PCa. 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
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According to the current standards, the local staging is ba-
sed on clinical examination (digital rectal exam – DRE) or 
a transrectal ultrasound (TRUS) [2]. Apart from the clinical 
examination and TRUS, local staging can also be performed 
based on mpMRI. MpMRI provides valuable information about 
the clinical significance and localization of the lesion [6]. This 
information is used to qualify the patient for a prostate biopsy. 
According to the current guidelines, it is recommended to 
perform mpMRI in suspected PCa before the first prostate 
biopsy [2]. Moreover, mpMRI, in the case of PCa, allows for 
a characterization of such clinical parameters as lesion size, 
possible EPE or seminal vesicle invasion (SVI) [6]. The above 
information allows for an estimation of the appropriate risk 
group of disease progression, choose the treatment method 
(RP vs. RT), or plan the extension of the RP. Nevertheless, mpMRI 
is still not validated as a diagnostic tool for local staging and 
treatment planning [2, 7, 8].
The study aimed to evaluate the utility of mpMRI in the 
prediction of EPE and the impact of EPE on the occurrence of 
BCR in patients qualified for RP.
Material and methods
The study group consisted of 61 patients diagnosed with PCa who 
underwent laparoscopic RP. RP was performed either by the trans- 
or retroperitoneal approach. An extended lymphadenectomy was 
performed in the case of high-risk and intermediate-risk cancer 
with a predicted probability of lymph node involvement above 
7%, according to the Briganti 2017 model [9]. The operation was 
performed with bilateral or unilateral NVB preservation or without 
NVB preservation. The NVB preserving technique involved inter- or 
intra-fascial dissection of the bundles, according to Walz [10]. The 
procedures without NVB preservation involved a wide extra-fascial 
prostatectomy [10]. The decision to preserve NVB was made 
depending on the EAU risk group. The preoperative risk of EPE 
was determined according to the Martini et al. model [11]. The 
decision to preserve NVB was also influenced by comorbidities, 
erectile dysfunction present before the planned procedure, age, 
and the patient’s preferences. 
The biopsy material and specimen acquired during RP 
underwent histopathological assessment conducted by three 
pathologists in accordance with the guidelines of the Interna-
tional Society of Urological Pathology (ISUP) 2014 in the field 
of pathomorphological diagnosis of PCa [12].
The study used mpMRI obtained when qualifying the pa-
tients for the first biopsy due to suspected PCa 1.5T (GE Health-
care Medical System Optima MR360, Chicago, IL, USA) and 3T 
equipment (Siemens HealthCare Magnetom Skyra, Erlangen, 
Germany) were utilized using 12- or 18-channel Body Matrix 
coils. The mpMRI scheme followed the PIRADS v. 2.0 guidelines 
of the American College of Radiology (ACR) [6]. It included 
a multiplanar assessment of the prostate in T1- and T2-weighted 
images, diffusion weighted imaging (DWI) and a dynamic con-
trast-enhanced (DCE) MRI. Apparent diffusion coefficient (ADC) 
maps were developed automatically. The mpMRI was evaluated 
by four radiologists experienced in prostate imaging who knew 
the PSA levels and rectal examination (DRE).
Based on mpMRI, a targeted cognitive biopsy of the prosta-
te combined with a systematic biopsy was performed, guided 
with transrectal ultrasound using a biplane transducer with 
simultaneous imaging of both planes (BK Medical Flex 400, 
Herlev, Denmark).
The biopsy was performed according to the scheme re-
commended by the European Society of Urology (EAU) [2], 
6–8 specimens were collected from each lobe, plus additionally 
2–4 specimens from the suspicious lesion depending on its 
size [2, 13, 14]. The biopsy was performed by four urologists. 
BCR was diagnosed when two PSA levels above 
0.2 ng/ml were obtained. PSA was monitored every three 
months during the first year and every six months in conse-
cutive years.
Statistical analysis
The analyzed parameters were described using an arithmetic 
mean, standard deviation, and median. The normality of distri-
bution was verified using the Shapiro-Wilk test in each of the 
analyzed groups. In a normal distribution, the t-Student test for 
independent variables was used to compare the two groups. In 
the case of non-normal distribution, the non-parametric Mann-
-Whitney test was applied. Categorical variables in individual 
groups were described using percentage values; they were 
compared using the Chi2 test with the Yates correction and 
with Fisher’s exact test. Receiver operating characteristic (ROC) 
curves were determined for the analyzed parameters (Martini 
model and mpMRI). AUC (area under curve) was subsequently 
calculated, and their significance was analyzed. Cut-off points 
for which sensitivity and specificity reach optimal values were 
determined for parameters with significant AUC (Youden point). 
Kaplan-Meier analysis and the log-rank test were used to 
compare BCR-free survival for patients with EPE in mpMRI. 
For BCR risk factors, hazard ratios (HRs) with 95% confidence 
intervals (CIs) were determined using the Cox model. The uni-
variate and multivariate model was established. The assumed 
p-value was <0.05. The IBM SPSS Statistics statistical package 
was used for the calculations. 
Results
Table I presents the clinical characteristics of 61 patients 
undergoing RP (n = 61). 19 patients (n = 19) were diagno-
sed with EPE(+) and 42 (n = 42) without EPE (–) in the final 
histopathological report post RP. Patients with EPE(+) diffe-
red statistically significantly from patients without EPE(–), 
in  terms of the following clinical parameters: ISUP grade 
in the preoperative biopsy, maximum index lesion (IL) di-
mension in mpMRI, EPE diagnosis in mpMRI, ISUP Grade 
in the postoperative report, the incidence of PSM, and the 
incidence of BCR in follow-up. 
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Analysis using the ROC curve showed that preoperati-
ve mpMRI might predict the presence of EPE of PCa with 
a sensitivity and specificity of 47.4% and 85.7%, respectively 
(AUC 0.66, 95% CI: 0.51–0.82, p = 0.046). Taking into account 
the results of the first statistical analysis, which indicate that 
EPE may also be dependent on other clinical parameters, we 
examined the sensitivity and specificity of the Martini model, 
which uses the following data: PSA level, EPE status in mpMRI, 
ISUP Gleason grade, and the percentage of the biopsy speci-
men involvement. The Martini model’s sensitivity was higher, 
but the specificity was lower than that of mpMRI and was 
84.2% and 66.7%, respectively (AUC 0.78, 95% CI: 0.66–0.89, 
p < 0.001) (fig. 1).
All patients in the study were subject to follow-up. 
The mean follow-up was 38 months (95% CI: 34.0–42.5 mon-
ths). Patients with pEPE(+) more frequently experienced BCR 
42% (n = 8) vs. pEPE(–) 7% (n = 3) (HR 6.4, 95% CI: 1.7–24). 
Using univariate and multivariate Cox analysis, it was exami-
ned whether other clinical factors may also influence the oc-
currence of BCR. Previous prognostic factors influencing the 
patient’s prognosis (PSA, ISUP grade, DRE, prostate volume, 
SM) were analyzed, taking into account mpMRI (PIRADS of IL, 
EPE status, largest IL dimension) (tab. II). The final Cox model 
showed that EPE in mpMRI was an independent factor that 
increased the likelihood of BCR – HR 6.6 (95% CI: 1.8–24.1). 
Table I. Clinical characteristics of patients. Comparison of clinical data between pEPE(–) and pEPE(+) patients
Total n (%) or median Overall





pEPE(+) vs. pEPE(–) p value
age (median) 65 65.7 63.4 NS
PSA (ng/ml) 8.46 8.01 9.47 NS





















































BCR(+) 11 (18) 3 (7.1) 8 (42.1) *










PSM 18 (29.5) 8 (19) 10 (52.6) *
PSA – prostate specific antigen; PSAD – PSA density; DRE – digital rectal exam; ISUP grade – 2014 International Society of Urological Pathology Grade; PIRADS – Prostate Imaging 
Reporting and Data System; mpMRI – multiparametric magnetic resonance imaging; EPE – extraprostatic extension (“–“absent, “+” present); pEPE – pathological extraprostatic 
extension (“–“ absent, “+” present); PZ – peripheral zone; non-PZ – zone other than peripheral; BCR – biochemical recurrence; PSM – positive surgical margin; IL – index lesion; NS – 















Figure 1. ROC curve – sensitivity and specificity of the Martini 
nomogram for EPE prediction before RP
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Another important factor, also significantly increasing the risk 
of BCR, was the presence of PSM in the postoperative report 
– HR 7.1 (95% CI: 1.9–26.7). Based on the above analysis, the 
Kaplan-Meier curve was determined for EPE assessment in 
mpMRI (fig. 2).
Discussion
The results obtained indicate that preoperative mpMRI may be 
a useful tool in local staging of PCa and for the prediction of 
recurrence; they are to a large extent consistent with the results 
of other similar studies [7, 8, 15, 16]. The mpMRI parameters 
analyzed by other researchers included: PIRADS score, volume 
and location of index lesions, presence of EPE, and/or SVI. Mo-
reover, taking into account mpMRI parameters in conjunction 
with other clinical data, such as PSA levels and prostate biopsy 
reports, may contribute to a significant improvement in local 
staging. An example of this strategy is the model according to 
Martini et al., which takes into account mpMRI, PSA levels, and 
a report of the targeted biopsy based on MRI [11].
This retrospective study is one of the few studies available 
in the literature, which indicates that mpMRI and the Martini 
model may be tools that are helpful in determining the pre-
sence of EPE before surgical treatment [8, 11]. The sensitivity 
and specificity of mpMRI in assessing EPE in our study were 
47.4% and 85.7%, respectively, while for the Martini model – 
84.2% and 66.7%, respectively. The meta-analysis conducted 
by de Rooij, assessing the diagnostic utility of mpMRI in the 
prediction of stage T3a (EPE), indicated a sensitivity of 0.57 (95% 
CI: 0.49–0.64) and a specificity of 0.91 (95% CI: 0.88–0.93) [8]. 
When creating this predictive model for the presence of EPE, 
Martini estimated the sensitivity of mpMRI alone at 40.7%. [11]. 
Then, considering the mpMRI and clinical variables, the cre-
ated model resulted in a higher diagnostic value than mpMRI 
alone (AUC for mpMRI 0.68 vs. AUC for the model 0.82) [11]. 
We obtained similar results in our research. 
Our study also confirmed the relationship between the 
presence of EPE in the postoperative histopathological report 
and an increased risk of BCR. Moreover, we demonstrated 
that EPE in preoperative mpMRI might also be an essential 
pre-surgical factor increasing the risk of BCR after RP. There-
fore, the results obtained in our study indicate that mpMRI 
may improve the prediction of possible disease recurrence 
by improving local disease staging. In a study with a similar 
methodology, conducted on a large group of respondents 
(n = 804), Gandalgia et al. proved that preoperative information 
obtained from mpMRI and the report of systematic biopsy 
combined with a targeted biopsy based on mpMRI allows 
stratification of PCa recurrence after RP [15]. When assessing 
the influence of preoperative factors on BCR, Manceau et al. 
also proved that patients with EPE(+) diagnosed in mpMRI at 
the treatment planning stage more frequently experience BCR 
after RP [16]. Moreover, they showed a correlation between 
the occurrence of BCR and higher PIRADS scores, the greater 
Table II. Univariate and multivariate Cox regression analysis of clinical factors for BCR in patients with localized PCa after RP
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
DRE, ref. normal 0.96 (0.28–3.3) 0.94
NA
PSA 0.95 (0.81-1.1) 0.4
biopsy ISUP grade, ref. grade 1 1.76 (0.56–5.8) 0.35
prostate volume 0.97 (0.92–1.0) 0.33
max diameter of IL in mpMRI (mm) 1.04 (0.97–1.1) 0.26
PIRADS, ref. ≤3 1.025 (0.3–3.6) 0.97
mpMRI – EPE, ref. EPE(–) 3.9 (1.2–12.9) 0.02 6.6 (1.8–24.1) 0.005
SM, ref. negative 4.7 (1.4–16.1) 0.01 7.1 (1.9–26.7) 0.004
DRE – digital rectal exam;  PSA – prostate specific antigen; ISUP grade – 2014 International Society of Urological Pathology Grade; PIRADS – Prostate Imaging Reporting and Data 
System; mpMRI – multiparametric magnetic resonance imaging; EPE – extraprostatic extension; BCR – biochemical recurrence; SM – surgical margins; IL – index lesion; NA – not 
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Figure 2. Kaplan-Meier survival curves for biochemical-free survival in 
patients with positive (+) and negative (–) mpMRI EPE
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maximum dimension of MRI lesions, and a higher ISUP Gleason 
grade in fusion biopsy [16]. 
From a clinical perspective, the presence of EPE in mpMRI 
may be a predictive factor for the risk of adjuvant RT imple-
mentation after RP. This knowledge at the treatment planning 
stage can help in the choice of a treatment method, i.e., RP 
vs. RT. If surgical treatment is chosen, the information about 
the presence of EPE in mpMRI and its location can be used 
to plan the procedure’s technique and make decisions, for 
example, regarding the preservation of nerve bundles. It has 
been proven that planning RP based on mpMRI changes the 
operator’s decision to preserve NVB in 35% (95% CI: 29–41%) of 
cases; this strategy is correct in 77% (95% CI: 72–81%) of cases 
and does not worsen oncological outcomes [17]. 
Our study has several limitations. The first significant li-
mitation is that it was conducted on a small group studied in 
one center. The second limitation is the lack of assessment of 
the extent of EPE and its detailed location, which, according 
to available knowledge, may also be a significant factor influ-
encing the risk of BCR. 
Conclusions
MpMRI and the Martini model are helpful tools in the local sta-
ging of patients with PCa. Preoperative use of mpMRI can predict 
oncological treatment outcomes in patients with PCa after RP.
Conflict of interest: none declared
Natalia Majchrzak
Poznan District Hospital 
Transplantology, General Surgery and Urology Department 
ul. Juraszów 7–19 
60-479 Poznań, Poland 
e-mail: drmajchrzak@gmail.com
Received: 7 Apr 2021 
Accepted: 17 Apr 2021
References
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality 
worldwide: sources, methods and major patterns in GLOBOCAN 2012. 
Int J Cancer. 2015; 136(5): E359–E386, doi: 10.1002/ijc.29210, indexed 
in Pubmed: 25220842.
2. Mottet N, van den Bergh RCN, Briers E et al. European Association of 
Urology Guidelines. 2020 Edition. [Internet]. Vol. presented at the EAU 
Annual Congress Amsterdam 2020. European Association of Urology 
Guidelines Office; 2020. http://uroweb.org/guideline/prostate-cancer/.
3. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of pro-
gression after PSA elevation following radical prostatectomy. JAMA. 
1999; 281(17): 1591–1597, doi: 10.1001/jama.281.17.1591, indexed in 
Pubmed: 10235151.
4. Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic Value of 
Biochemical Recurrence Following Treatment with Curative Intent for 
Prostate Cancer: A Systematic Review. Eur Urol. 2019; 75(6): 967–987, 
doi: 10.1016/j.eururo.2018.10.011, indexed in Pubmed: 30342843.
5. Suardi N, Ficarra V, Willemsen P, et al. Long-term biochemical recurrence 
rates after robot-assisted radical prostatectomy: analysis of a single-
-center series of patients with a minimum follow-up of 5 years. Urology. 
2012; 79(1): 133–138, doi: 10.1016/j.urology.2011.08.045, indexed in 
Pubmed: 22088567.
6. Barentsz JO, Choyke PL, Cornud F, et al. PI-RADS Prostate Imaging - Re-
porting and Data System: 2015, Version 2. Eur Urol. 2016; 69(1): 16–40, 
doi: 10.1016/j.eururo.2015.08.052, indexed in Pubmed: 26427566.
7. Somford DM, Hamoen EH, Fütterer JJ, et al. The predictive value of 
endorectal 3 Tesla multiparametric magnetic resonance imaging for 
extraprostatic extension in patients with low, intermediate and high 
risk prostate cancer. J Urol. 2013; 190(5): 1728–1734, doi: 10.1016/j.
juro.2013.05.021, indexed in Pubmed: 23680307.
8. de Rooij M, Hamoen EHJ, Witjes JA, et al. Accuracy of Magnetic Resonan-
ce Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-ana-
lysis. Eur Urol. 2016; 70(2): 233–245, doi: 10.1016/j.eururo.2015.07.029, 
indexed in Pubmed: 26215604.
9. Gandaglia G, Fossati N, Zaffuto E, et al. Development and Internal Vali-
dation of a Novel Model to Identify the Candidates for Extended Pelvic 
Lymph Node Dissection in Prostate Cancer. Eur Urol. 2017; 72(4): 632–
640, doi: 10.1016/j.eururo.2017.03.049, indexed in Pubmed: 28412062.
10. Walz J, Epstein JI, Ganzer R, et al. A Critical Analysis of the Current 
Knowledge of Surgical Anatomy of the Prostate Related to Optimisa-
tion of Cancer Control and Preservation of Continence and Erection 
in Candidates for Radical Prostatectomy: An Update. Eur Urol. 2016; 
70(2): 301–311, doi: 10.1016/j.eururo.2016.01.026, indexed in Pubmed: 
26850969.
11. Martini A, Gupta A, Lewis SC, et al. Development and internal validation 
of a side-specific, multiparametric magnetic resonance imaging-based 
nomogram for the prediction of extracapsular extension of prostate 
cancer. BJU Int. 2018; 122(6): 1025–1033, doi: 10.1111/bju.14353, 
indexed in Pubmed: 29676063.
12. Epstein JI, Egevad L, Amin MB, et al. Grading Committee. The 2014 
International Society of Urological Pathology (ISUP) Consensus Confe-
rence on Gleason Grading of Prostatic Carcinoma: Definition of Grading 
Patterns and Proposal for a New Grading System. Am J Surg Pathol. 
2016; 40(2): 244–252, doi: 10.1097/PAS.0000000000000530, indexed 
in Pubmed: 26492179.
13. Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy 
methods in the investigation of prostate cancer: a systematic review. 
J Urol. 2006; 175(5): 1605–1612, doi: 10.1016/S0022-5347(05)00957-2, 
indexed in Pubmed: 16600713.
14. Shariat, SF, Roehrborn, CG Using biopsy to detect prostate cancer. Rev 
Urol. 2008; 10: 262–280.
15. Gandaglia G, Ploussard G, Valerio M, et al. Prognostic Implications 
of Multiparametric Magnetic Resonance Imaging and Concomitant 
Systematic Biopsy in Predicting Biochemical Recurrence After Radical 
Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Re-
sonance Imaging-targeted Biopsy. Eur Urol Oncol. 2020; 3(6): 739–747, 
doi: 10.1016/j.euo.2020.07.008, indexed in Pubmed: 32847747.
16. Manceau C, Beauval JB, Lesourd M, et al. MRI Characteristics Accurately 
Predict Biochemical Recurrence after Radical Prostatectomy. J Clin Med. 
2020; 9(12), doi: 10.3390/jcm9123841, indexed in Pubmed: 33256176.
17. Kozikowski M, Malewski W, Michalak W, et al. Clinical utility of MRI in the 
decision-making process before radical prostatectomy: Systematic re-
view and meta-analysis. PLoS One. 2019; 14(1): e0210194, doi: 10.1371/
journal.pone.0210194, indexed in Pubmed: 30615661.
